氨氯地平联合二甲双胍治疗肥胖型轻中度高血压的疗效分析

The Analysis of the Efficacy for Amlodipine Combined with Metformin in the Treatment of Obese Mild to Moderate Hypertension

目的:探讨氨氯地平联合二甲双胍用于肥胖型轻中度高血压治疗的临床效果。方法:选取肥胖型轻中度高血压患者150例,按照随即编号法分为对照组73例和观察组77例。对照组给予氨氯地平治疗,观察组在对照组基础上加用二甲双胍进行治疗。对两组患者的血压控制情况以及多项生活指标进行监测,并评价治疗效果。结果:经过治疗两组患者血压与治疗前相比均明显下降,但观察组患者降低更为明显,而且观察组患者治疗有效率明显高于对照组,比较差异均有统计学意义(P<0.05)。经过治疗,对照组患者仅有HbA1C与治疗前相比明显降低,其他指标与治疗前比较差异无统计学意义(P>0.05)。观察组患者各项指标与治疗前相比均明显降低,且低于对照组患者治疗后,比较差异均有统计学意义(P<0.05)。结论:对伴有肥胖的轻中度高血压患者实施氨氯地平和二甲双胍联合治疗在控制患者血压和血脂方面具有较好的效果,可以作为临床首选的联合用药方案进行推广。

Objective： To investigate the clinical effect for amlodipine combined with metformin in the treatment of obese mild to moderate hypertension.Method： One hundred and fifty obese patients with mild to moderate hypertension were selected, and they were randomly divided into 73 cases of the control group and 77 cases of the observation group.The control group was treated with amlodipine treatment, and the control group was treated with mefformin treatment on the basis of the control group.The blood pressure control and numerous life indicators for monitoring the therapeutic effect of the two groups were evaluated.Result： After treatment, the blood pressure of the two groups decreased significantly compared with before treatment, and the control group was more obvious.The treatment efficacy rate of the observation group was significantly higher than the control group, there were statistically significant differences （ P〈0.05 ） .After treatment, the HbA1C in the control group was only significantly lower than before treatment.Other indictors compared with before treatment, there were no significant differences （ P〉0.05 ） .The indicators compared with before treatment in the control group were significantly lower, and lower than the control group after treatment, the differences were obvious, and there were statistically significant differences （ P〈0.05 ） .Conclusion： The amlodipine mefformin in the treatment of obese mild to moderate hypertension has a good effect, can be used as the preferred combination for clinical programs.